Shopping Cart
- Remove All
Your shopping cart is currently empty
Ginsenoside Ra1
🥰Excellent
Catalog No. TN1096Cas No. 83459-41-0
Ginsenoside Ra1, a component from ginseng, exhibits significant inhibitory effects on protein tyrosine kinase (PTK) activation induced by hypoxia/reoxygenation (H/R).
Ginsenoside Ra1
🥰Excellent
Purity: 97.44%
Catalog No. TN1096Cas No. 83459-41-0
Ginsenoside Ra1, a component from ginseng, exhibits significant inhibitory effects on protein tyrosine kinase (PTK) activation induced by hypoxia/reoxygenation (H/R).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $115 | In Stock | |
| 5 mg | $280 | In Stock | |
| 10 mg | Inquiry | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Ginsenoside Ra1"
ZD1839
T1181184475-35-2
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
- $40
- $50
Size
QTY
CitedIbrutinib Cited
PCI-32765
T1835936563-96-1
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
- $36
Size
QTY
CitedDelgocitinib
JTE-052, Corectim（Delgocitinib）
T150961263774-59-9
Delgocitinib (JTE-052) is a specific JAK (Janus kinase) inhibitor with IC50 values of 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2 respectively. Delgocitinib is involved in various inflammatory and autoimmune diseases through JAK-dependent cytokines and can effectively suppress multiple cytokine signaling while inhibiting itching caused by cytokines. It is widely used to treat various inflammatory diseases, including autoimmune diseases and hypersensitivity reactions.
- $172
Size
QTY
Ruxolitinib Cited
INCB018424, (R)-Ruxolitinib
T1829941678-49-5
Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective. Rixolitinib exhibits antitumor activity and induces autophagy and apoptosis.
- $53
Size
QTY
CitedDeucravacitinib
BMS-986165
T146871609392-27-9
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
- $64
Size
QTY
Baricitinib Cited
LY3009104, INCB028050
T24851187594-09-7
Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9/5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.
- $43
Size
QTY
CitedGSK 3 Inhibitor IX Cited
MLS 2052, GSK 3 IX, BIO, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, 6-BIO
T1917667463-62-9
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.
- $37
Size
QTY
CitedTafetinib
SIM-010603, SIM010603, SIM 010603
T289111032265-57-8In house
Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity.
- $250
Size
QTY
Pacritinib Cited
SB1518
T6020937272-79-2
Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).
- $34
Size
QTY
CitedNVP-BSK805 2HCl (1092499-93-8(free base))
NVP-BSK805 dihydrochloride, NVP-BSK805 (dihydrochloride), BSK 805
T6294In house
NVP-BSK805 2HCl (1092499-93-8(free base)) (BSK 805)(IC50=0.5 nM), a specific and effective ATP-competitive JAK2 inhibitor, is more than 20-fold specificity over JAK1, JAK3 and TYK2.
- $32
Size
QTY
SAR-20347
Cited
SAR20347
T42101450881-55-6
SAR-20347 is an inhibitor of TYK2 and JAK1/2/3, with IC50 values of 0.6 nM, 23 nM, 26 nM, and 41 nM, respectively.
- $30
Size
QTY
CitedVidarabine Cited
Vira-A, Arabinosyladenine, Ara-A, Adenine Arabinoside, 9-β-D-Arabinofuranosyladenine
T15065536-17-4
Vidarabine (Adenine Arabinoside) is a nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
- $38
Size
QTY
CitedSelect Batch
Purity:97.44%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Ginsenoside Ra1, a component from ginseng, exhibits significant inhibitory effects on protein tyrosine kinase (PTK) activation induced by hypoxia/reoxygenation (H/R). |
| In vitro | Ginsenoside Ra1 showed significant inhibitory effects on protein tyrosine kinase (PTK) activation induced by an in vitro hypoxia/reoxygenation (H/R) model in cultured human umbilical vein endothelial cells (HUVEC)[1]. |
| Molecular Weight | 1211.38 |
| Formula | C58H98O26 |
| Cas No. | 83459-41-0 |
| Smiles | [H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@]3([H])CC[C@@]21C)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO[C@@H]2OC[C@H](O[C@]3([H])OC[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O |
| Relative Density. | 1.47 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Ginsenoside Ra1 | purchase Ginsenoside Ra1 | Ginsenoside Ra1 cost | order Ginsenoside Ra1 | Ginsenoside Ra1 chemical structure | Ginsenoside Ra1 in vitro | Ginsenoside Ra1 formula | Ginsenoside Ra1 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.